Table 2.

Effect of rD-mPGPtide on Reconstitution of Donor T and B Lymphocytes in the Haploidentical and MHC Class II-Disparate Strain Combinations

Strain CombinationTreatmentPhenotype, Day 30; Spleen (% donor/host)Phenotype, Day 72; Spleen* (% donor/host)Phenotype, Day 72;
T CellsB CellsT CellsB CellsLN* (% donor/host)
T CellsB Cells
(B6D2)F1 → (B6CB)F1 (800 cGy) PBS 8/47  5/26 7/59 6/39 6/28 
 rD-mPGPtide 32/11 ND 36/9 64/4 68/16 28/4 
 Anti-CD4 MoAb 29/14  32/10 61/5 61/20 27/5 
bm12 → B6-Ly5.2 (750 cGy) PBS 9/22 10/44 4/25  2/57  
 rD-mPGPtide 28/11 41/11 14/10 ND 37/13 ND 
 Anti-CD4 MoAb 21/9 56/6 15/8  31/14 
Strain CombinationTreatmentPhenotype, Day 30; Spleen (% donor/host)Phenotype, Day 72; Spleen* (% donor/host)Phenotype, Day 72;
T CellsB CellsT CellsB CellsLN* (% donor/host)
T CellsB Cells
(B6D2)F1 → (B6CB)F1 (800 cGy) PBS 8/47  5/26 7/59 6/39 6/28 
 rD-mPGPtide 32/11 ND 36/9 64/4 68/16 28/4 
 Anti-CD4 MoAb 29/14  32/10 61/5 61/20 27/5 
bm12 → B6-Ly5.2 (750 cGy) PBS 9/22 10/44 4/25  2/57  
 rD-mPGPtide 28/11 41/11 14/10 ND 37/13 ND 
 Anti-CD4 MoAb 21/9 56/6 15/8  31/14 

Data from one experiment representative of three separate experiments are presented as the percentage of positive cells, as analyzed by flow cytometry. Chimerism was determined using the following MoAb pairs: PE-anti-Thy1.2 (or B220) and FITC-anti-H2Kk, [(B6D2)F1 → (B6CB)F1 ]; PE-anti-Thy1.2 (or B220) and FITC-anti-CD45.1 (anti-Ly5.1) (bm12 → B6-Ly5.2). The mean of samples from five mice per group is presented for each individual treatment. The values in all rD-mPGPtide and anti-CD4 MoAb treatment groups were significantly different from those in the PBS control group, P ≤ .001.

Abbreviation: ND, not done.

*

Mice in the bm12 → B6-Ly5.2 strain combination were analyzed on day 60 after transplantation.

or Create an Account

Close Modal
Close Modal